Human Health and Disease · Lesson 8 of 11
Cancer: Cell-Cycle Dysregulation, Metastasis and Treatment
“Normal growth controls, genetic changes, benign and malignant tumours, metastasis, carcinogens, diagnosis and therapy.”
• Explain how normal cell division is regulated and how malignant transformation disrupts those controls. • Distinguish benign from malignant tumours and define metastasis. • Connect carcinogens, oncogenes and tumour suppressors to altered growth regulation. • Explain biopsy, histopathology, imaging and molecular approaches to detection. • Compare surgery, radiation, systemic drugs and immune-based treatments.
Normal tissue growth requires control of cell proliferation
Most cells in a multicellular organism do not divide without regulation. Cell-cycle checkpoints, signals from neighbouring cells, growth factors and mechanisms that eliminate damaged cells help maintain tissue structure. In culture, many normal cells respond to contact with surrounding cells by reducing proliferation, sometimes described as contact inhibition. Cancer arises when combinations of molecular changes disrupt normal control of cell growth, survival and tissue boundaries. Failure of contact inhibition is a useful illustration, but it is not the sole or universal molecular cause of every cancer.
Cells can acquire genetic changes during DNA replication or after exposure to damaging agents. Some inherited variants increase susceptibility to particular cancers, but the great majority of tumour development involves additional changes acquired during life. Mutations can activate genes that drive proliferation, disable mechanisms that normally restrict division or reduce the cell's capacity to repair damaged DNA. These alterations accumulate through selection of cell populations capable of surviving and reproducing despite ordinary tissue constraints.
Benign and malignant tumours
A tumour is an abnormal mass of tissue formed through unusual cellular growth or survival, although some cancers do not form solid masses. Benign tumours usually remain localised and do not metastasise; nevertheless, a benign mass can still cause serious harm by compressing a vital structure or altering hormone secretion. Malignant tumours invade surrounding tissue and may acquire the capacity to spread to distant sites. Their cells can differ from normal tissue in structure, division pattern and interactions with neighbouring cells. Malignancy is therefore a functional classification, not simply a judgment based on the tumour's size.
How metastasis produces growth at a distant site
Metastasis is the spread of malignant cells from a primary tumour to other parts of the body, where they may establish secondary tumours. Several difficult stages must occur: cells detach or invade surrounding tissue, enter blood or lymphatic vessels, survive transport, leave the circulation and adapt to a new microenvironment. Many released tumour cells do not successfully establish new growth. Once a distant colony is established, it is named by the origin of the original cancer, rather than automatically being classified as a new primary cancer of the organ where it appears.
Invasion and metastasis are two related but different properties. Invasion refers to cells entering and damaging adjacent tissue. Metastasis involves successful movement and establishment at a distant location. Growth of a local tumour can also compete for nutrients and promote formation of new blood vessels, but nutritional competition alone does not explain the whole disease. Distinguishing these mechanisms helps explain why malignant cancers are more challenging than many localised benign masses.
Carcinogens and altered growth-control genes
Carcinogens are physical, chemical or biological factors that increase cancer risk through mechanisms including DNA damage, chronic tissue injury or altered signalling. Ionising radiation such as X-rays can damage DNA; excessive ultraviolet radiation can produce specific DNA lesions. Tobacco smoke contains chemical carcinogens that increase risk of several cancers, especially those involving the lungs and airway. Some viruses can contribute to cancer by changing cell regulation or producing persistent conditions that favour malignant transformation, but most infections do not produce cancer.
Proto-oncogenes normally support regulated cell growth and survival. When particular changes make them excessively active, they become oncogenes capable of driving proliferation. Tumour suppressor genes help restrain abnormal growth or trigger protective responses, while DNA repair genes reduce accumulation of mutations. Alterations in these categories can interact during tumour progression. This mechanistic explanation is more accurate than the claim that a cancer cell simply decides not to follow instructions. Genes, proteins and tissue environment together shape behaviour.
Detection, diagnosis and treatment
An abnormality noticed on physical examination, imaging or laboratory assessment may require tissue sampling. A biopsy provides tissue for histopathological examination of stained sections under the microscope. Pathologists inspect cell architecture and other features to establish the nature of a suspicious lesion. Radiography, computed tomography using X-rays, and magnetic resonance imaging using magnetic fields and radiofrequency signals can help locate and characterise abnormalities. Imaging can show suspicious structures but does not always replace tissue diagnosis. Blood or bone-marrow tests may help investigate certain blood cancers, including leukaemias.
Molecular and antibody-based tests may identify tumour-associated proteins or genetic changes and help refine diagnosis, classification or treatment planning. Inherited susceptibility testing can be valuable for certain people and families, but a risk-associated variant does not mean cancer is inevitable. Appropriate prevention and detection depend on the cancer type, person's risk and available evidence. A tumour biopsy tests a disease that may be present, whereas inherited-gene testing may identify susceptibility without finding an existing tumour.
Treatment is selected according to cancer type, stage, molecular features and the person's health. Surgery may remove a localised tumour; radiotherapy directs ionising radiation toward cancer tissue while limiting exposure to surrounding structures. Chemotherapy uses drugs that interfere with cell growth or survival and can affect normal rapidly dividing cells, producing adverse effects such as hair loss or changes in blood-cell production. Some cancers respond to targeted agents acting on specific molecular abnormalities or to immunotherapies that help the immune system recognise or destroy tumour cells. Treatments are frequently combined, and outcome is not the same for every cancer.
| Concept | Meaning | Why it matters |
|---|---|---|
| Benign tumour | Localised abnormal growth without metastasis | May still cause harm from position or secretion |
| Malignant tumour | Cancerous growth capable of invasion | Can damage nearby tissue |
| Metastasis | Spread to a distant site | Requires invasion, transport and colonisation |
| Oncogene | Growth-promoting gene with abnormal activity | Can promote inappropriate proliferation |
| Biopsy | Sampling suspicious tissue | Supports microscopic diagnosis |
| Radiotherapy | Controlled ionising radiation treatment | Damages sensitive cancer cells |
| Immunotherapy | Treatments harnessing or modifying immune responses | Can act through tumour–immune mechanisms |
Cancer is not one single disease, and modern treatments include targeted medicines and immune-based approaches alongside surgery, radiation and cytotoxic chemotherapy. A benign tumour can still cause harm, while a malignant tumour's danger is not defined only by how quickly it divides.
Quick Quiz
Quiz
Which feature most clearly distinguishes malignant tumours from benign tumours?
What does metastasis mean?
What can a proto-oncogene become after certain activating changes?
What does biopsy most directly provide?
Which imaging method uses strong magnetic fields and radiofrequency signals rather than ionising X-rays?
Which is a recognised environmental chemical carcinogen source?
Which treatment class seeks to harness immune responses against cancer?
Practice Problems
- Explain the difference between benign and malignant tumours and why tumour size alone is insufficient.
- Describe metastasis as a sequence, identifying the major biological barriers a tumour cell must cross.
- Describe the relationships among carcinogens, proto-oncogenes, tumour suppressor genes and DNA repair genes.
- Compare biopsy, CT, MRI, chemotherapy, radiation and immune-based treatments.
- Explain why identifying an inherited cancer-susceptibility gene is different from finding an existing cancer.
A benign tumour usually remains confined to its site of origin and does not spread to distant tissues, although it may still cause damage through pressure or secretion. A malignant tumour can invade adjacent structures and potentially metastasise. A small malignant lesion may be dangerous because of its molecular properties and ability to invade, while a comparatively large benign lesion may remain localised. Classification therefore requires assessment of cell behaviour, architecture and sometimes molecular characteristics rather than size alone.
Key Takeaways
• Cancer involves disrupted regulation of cellular growth, survival and tissue behaviour. • Benign tumours do not metastasise, though they can still harm local tissues. • Malignant tumours can invade surrounding tissues and spread to distant sites. • Metastasis requires transport and successful growth outside the original tumour site. • Carcinogens and altered growth-control genes contribute to cancer risk. • Biopsy, imaging and molecular tests provide complementary diagnostic information. • Surgery, radiation, chemotherapy, targeted agents and immunotherapy treat cancers through different mechanisms.